Skip to main content
. 2022 Feb 24;13:856961. doi: 10.3389/fphar.2022.856961

FIGURE 3.

FIGURE 3

Simulated relationship between target expression and bivalent selectivity. (A) Simulation of select EGFR targeted therapies, nimotuzumab (KD = 2.1 × 10−8 mol/L; kon = 5.2 × 104 (s mol/L)−1; koff = 1.1 × 10−3 s−1) and cetuximab (KD = 1.8 × 10−9 mol/L; kon = 3.1 × 106 (s mol/L)−1; koff = 5.8 × 10−3 s−1) between EGFR expression and maximum proportion of bivalent complex formed. (B) Low affinity of nimotuzumab relative to cetuximab prevents accumulation of antibody on healthy cells. Increasing target density promotes bivalent binding and retention of antibody on tumor cells.